Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
DXB
vs
S
S&P/ASX 300
DXB
Over the past 12 months, DXB has underperformed S&P/ASX 300, delivering a return of -58% compared to S&P/ASX 300's 2% drop.
Stocks Performance
DXB vs S&P/ASX 300
Performance Gap
DXB vs S&P/ASX 300
Performance By Year
DXB vs S&P/ASX 300
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Dimerix Ltd
Glance View
Dimerix Ltd is a drug-development company focused on kidney disease and other serious conditions. It does not sell a finished medicine to patients; instead, it develops drug candidates and the scientific tools used to find new treatments. Its lead work centers on DMX-200, a kidney-disease therapy in clinical development, and on its receptor-based discovery platform, which it uses to identify and test new drug targets. The company’s main customers are not end patients but pharmaceutical partners, research collaborators, and investors that support its development programs. Dimerix makes money mainly through research and licensing arrangements, as well as funding tied to its development work. In a business sense, it sits in the middle of the drug pipeline: it helps move early scientific ideas toward clinical testing and, if successful, toward partnering or commercialization. What makes Dimerix different is its focus on kidney disorders and its use of a receptor-interaction discovery method to find drug candidates that standard screening can miss. That gives it a more specialized role than a broad biotech company. Its value comes from building assets that can be developed internally or licensed to larger drugmakers with the manufacturing, regulatory, and sales reach to bring them to market.